According to the external analysis, Solana rebounded earlier this month after falling to the vicinity of $62, at a price of 70 above. At the same time, the silo of the derivatives market rebounded, indicating that part of the funds had been re-established and that the market had begun to focus on whether the recovery could continue upward.

It's a short-line support around $62.

The article mentions that SOL had previously returned from $78 to the vicinity of $61, then gradually raised the low point and rebounded to the vicinity of $75. This trend meant that the price had temporarily secured the repair structure after a sharp fall, and the purchase was still in a higher position.

In the short-line zone, between 74 and 75 dollars has been blocked on several occasions, becoming the current local drag zone. If this position is delayed, prices may still sustain shocks.

We're back on the line.

According to the article, during the previous downturn, the SOL derivatives contract shrunk significantly, while the recent rebound in prices was accompanied by a renewed rise in the unstabilized contract, reflecting the emergence of a new position in the market.

Such changes usually mean that the passive silo phase has weakened after the collapse and some traders have begun to re-engage. If the price continues to rise in step with the hold, the rebound is expected to continue further.

  • Current focus: Will 70 above remain stable
  • High resistance bits: $76, $86, $95 to $100
  • Below: 67 to 68 dollars, 62.8 dollars

Can we go back 90 dollars?

According to the article, if SOL continued to hold $70 and repositioned for $76, the price might have been around $86. If this area is recovered, the 95 to 100 dollars range will be the main area of resistance in the next phase.

However, if the monthly line is collected between US$ 67 and US$ 68, the price may resonate with US$ 62.8. In the event that the position is lost, short-line restoration of the rhythm may be interrupted and the market will reassess the lower space.

As the quarterly intake approaches, the viability of $70 above is becoming the key observation point for determining the continuation of the round.